Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$13.70M$13.70Mno prior Q2 2020 on file Net Income-$6.83M-$6.83MN/M vs Q2 2020 EPS Diluted-$0.10-$0.10N/M vs Q2 2020 Operating Income-$6,705,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,052,000N/M Margins · derivedOperating margin-49.0%
Net margin-49.9%
ended Jun 30, 2021 · filed Aug 5, 2021 · 36 d after period end